**COMPANY UPDATE**

**ANTICIPATING A LEAP AHEAD IN CLINICAL STUDIES**

The company reported 2018 full-year financial results and provided a corporate update. In 2019 we expect the lead clinical asset, firibastat, to move further in clinical development. In line with previous guidance, QUANTUM GENOMICS is planning to initiate the Phase 3 study of firibastat in resistant hypertension in 2H19. Prior to that, we expect the company to communicate the results of the post-Phase 2b meeting with the FDA, which could outline the design of the Phase 3 study. Additionally, we expect the company to start the Phase 2 clinical study of firibastat in heart failure in 2Q19. Following 2018 results, we have update our financial model. We reiterate our BUY rating and TP of €9.0.

Anticipating the firibastat program to advance in rHTN

Quantum Genomics is developing a novel therapy to treat cardiovascular complications, such as hypertension (HTN) and heart failure (HF). The company’s most advanced therapy, firibastat, is based on novel approach to target brain aminopeptidase A (BAPA), an enzyme that is present in the brain and can regulate peripheral blood pressure. Firibastat has already shown positive antihypertensive activity in the Phase 2b NEW-HOPE study, and we currently expects the results from the FDA meeting to outline the clinical path forward for the asset in treatment of resistant HTN. According to the company, the following Phase 3 study could be initiated in 2H19. Additionally, the company is developing a controlled-release formulation of the drug, which could be taken once-daily compared to current twice-daily formulation. Quantum Genomics initiated the clinical study in healthy volunteers to evaluate the pharmacokinetics of the new formulation and the readout of the study could be expected in 2Q19. We note that in accordance with the study results, the company is planning to use controlled-release formulation of firibastat in the upcoming Phase 3 study in rHTN. We currently project firibastat to be launched in the US and the EU in 2023, generating risk-adjusted revenues of €16M and growing to €495M by 2031.

New preclinical data in HF support the initiation of clinical study

The company is also pursuing the development of firibastat in HF, where the drug has already shown encouraging preclinical activity. Recently, the company announced the publication of 2 scientific articles that further support the potential of firibastat in this indication. The first article showed that firibastat reduced cardiac dysfunction after myocardial infarction (MI) in the murine model. Importantly, when compared to losartan, current standard of treatment, firibastat was as effective but did not induce side effects, such as hypotension or risk of degrading renal function. The second paper, showed that firibastat administered to mice within 48 hours after MI for 4–8 weeks was as effective as enalapril, a medication approved for symptomatic heart failure. Thus, we believe these results could further support the development of firibastat in heart failure. According to company the Phase 2b QUORUM study in patients suffering from acute MI could begin in 2Q19 and we expect topline results in 2H20. We currently expect firibastat to reach the market for HF in 2025, generating risk-adjusted revenues of €25M and growing to €412M by 2031.

<table>
<thead>
<tr>
<th>in € / share</th>
<th>2018e</th>
<th>2019e</th>
<th>2020e</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted EPS</td>
<td>-0,64</td>
<td>-0,60</td>
<td>-0,22</td>
</tr>
<tr>
<td>chg.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>estimates chg</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>au 31/12</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>PE</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>EV/Sales</td>
<td>n.s.</td>
<td>n.s.</td>
<td>5,94x</td>
</tr>
<tr>
<td>EV/EBITDA</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>EV/EBITA</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>FCF yield*</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>Div. yield (%)</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

* After tax op. FCF before WCR

**key points**

- Share price (€): 5,34
- Number of Shares (m): 16,4
- Market cap. (€m): 87
- Free float (€m): 68
- ISIN: FR0011648971
- Ticker: ALQGC-FR
- DJ Sector: Health Technology

<table>
<thead>
<tr>
<th>1m</th>
<th>3m</th>
<th>Ytd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolte perf.</td>
<td>+14,0%</td>
<td>+0,0%</td>
</tr>
<tr>
<td>Relative perf.</td>
<td>+14,3%</td>
<td>-11,1%</td>
</tr>
</tbody>
</table>

Source: Factset, Invest Securities estimates

**continued on next page**
Financial update

On March 28, QUANTUM GENOMICS reported abridged 2018 full-year financial results. For 2018, the company reported income of €0.07M and net loss of €12M, in-line with our estimates. For 2019, we project no revenues and a net loss of €11.2M. The company ended 2018 with €14.9M in cash and cash equivalents, resulted from the capital raise through equity line with Kepler Chevreux. In 1Q19, Quantum Genomics reported withdrawal of additional €2.6M and, we believe, the resulting cash and cash equivalents would be sufficient to maintain company’s operations into 2H20. We note that company has additional €9.1M remaining under the equity line agreement. We have updated our model to reflect the reported 2018 financial results.
INVESTMENT CASE

The company’s most advanced asset, firibastat, achieved positive topline results in the Phase 2b study in high-risk hypertension. The company could initiate the prospective Phase 3 study in resistant hypertension in 2H19. If successful, firibastat could become first-in-class antihypertensive drug with the potential launch in the US and EU in 2023. In our view, Quantum Genomics with the promising mid-stage clinical program, is an attractive option for investors interested in cardiovascular space.

FINANCIAL DATA

### Share information

<table>
<thead>
<tr>
<th>Year</th>
<th>Published EPS (€)</th>
<th>Adjusted EPS (€)</th>
<th>Dividend</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>-0.32</td>
<td>-0.28</td>
<td>0.00</td>
</tr>
<tr>
<td>2014</td>
<td>-0.32</td>
<td>-0.27</td>
<td>0.00</td>
</tr>
<tr>
<td>2015</td>
<td>-0.45</td>
<td>-0.38</td>
<td>0.00</td>
</tr>
<tr>
<td>2016</td>
<td>-0.51</td>
<td>-0.37</td>
<td>0.00</td>
</tr>
<tr>
<td>2017</td>
<td>-0.58</td>
<td>-0.51</td>
<td>0.00</td>
</tr>
<tr>
<td>2018e</td>
<td>-0.73</td>
<td>-0.64</td>
<td>0.00</td>
</tr>
<tr>
<td>2019e</td>
<td>-0.68</td>
<td>-0.60</td>
<td>0.00</td>
</tr>
<tr>
<td>2020e</td>
<td>-0.26</td>
<td>-0.22</td>
<td>0.00</td>
</tr>
</tbody>
</table>

### Published EPS vs Consensus

- Diff. I.S. vs Consensus
  - 2013: n.s.
  - 2014: -31.6%
  - 2015: -21.8%
  - 2016: -30.5%
  - 2017: -47.7%
  - 2018e: -31.8%
  - 2019e: -41.4%
  - 2020e: n.s.

### Valuation ratios

- EV/Sales: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- VE/EBITDA: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- VE/EBITA: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Op. FCF bef. WCR yield: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Op. FCF yield: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Div. yield (%): n.s. n.s. n.s. n.s. n.s. n.s. n.s.

- EV/Sales: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- VE/EBITDA: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- VE/EBITA: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Op. FCF bef. WCR yield: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Op. FCF yield: n.s. n.s. n.s. n.s. n.s. n.s. n.s.
- Div. yield (%): n.s. n.s. n.s. n.s. n.s. n.s. n.s.

NB: valuation based on annual average price for past exercise

### Income statement (€m)

- Sales: 0 0 0 0 0 0 0 14
- EBITDA: -2 -2 -4 -6 -10 -14 -13 -5
- EBIT: -2 -2 -4 -6 -10 -14 -13 -5
- Financial result: 0 0 0 0 0 0 0 0
- Corp. tax: 0 0 1 1 1 1 2 1
- Net attributable profit: -2 -2 -4 -5 -9 -12 -11 -4

### Cash flow statement (€m)

- Operating FCF bef. WCR: -2 -3 -4 -6 -10 -14 -13 -5
- Change in WCR: 1 -1 0 0 0 0 0 0
- Operating FCF: -1 -3 -4 -7 -9 -14 -13 -5
- Capital increase/decrease: 1 4 12 8 15 3 0
- Acquisitions/disposals: 0 0 0 0 0 0 0 0
- Other adjustments: 0 0 1 2 1 2 2 1

Source: company, Invest Securities Estimates
**STRENGTHS**
- First-in-class mechanism of action
- Mid-stage clinical programs
- Secured financing through equity line

**WEAKNESSES**
- Competitive market
- More advanced competitor
- Potential dilution

**OPPORTUNITIES**
- Commercialization agreement
- Earlier-than-expected market approvals
- Marketing in other territories

**THREATS**
- Clinical and regulatory risks
- Commercial risks
- Legal risks

**SHARE PRICE CHANGE FOR 5 YEARS**

**DETECTION OF CONFLICTS OF INTEREST**

<table>
<thead>
<tr>
<th>Company</th>
<th>Corporate Finance</th>
<th>Treasury stocks holding</th>
<th>Prior communication to company</th>
<th>Analyst's personal interest</th>
<th>Liquidity contract</th>
<th>Listing Sponsor</th>
<th>Research Contract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantum Genomics</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**DISCLAIMER**

This document does not constitute an offer to buy or sell securities issued by the above mentioned company. The foregoing information, forecasts and opinions, are the result of the best efforts of those involved in their compilation, and are believed to be coherent and reasonable. The directors, managers and employees of Invest Securities cannot be held responsible for the accuracy and completeness of this document's contents as a consequence of any form of guarantee. No individual can be held liable for any loss resulting from the use of this document, or any element thereof, to invest in marketable securities. The conditions for the preparation, production and distribution of this research are fully compliant with articles 321-122 to 321-142 of the "AMF"– the French financial markets regulator.
BIOTECH

QUANTUM GENOMICS

DIRECTION

Marc-Antoine Guillon
Président
+33 1 44 88 77 80
maguillon@invest-securities.com

Jean-Emmanuel Vernay
Directeur Général
+33 1 44 88 77 82
jevernay@invest-securities.com

Anne Bellavoine
Directeur Général Délégué
+33 1 55 35 55 75
abellavoine@invest-securities.com

Pascal Hadjedj
Directeur Général Adjoint
+33 1 55 35 55 61
phadjedj@invest-securities.com

Maxime Dubreil
Responsable Recherche
+33 1 44 88 77 98
mdubreil@invest-securities.com

Johann Carrier
Stock-Picking
+33 1 44 88 77 88
jcarrier@invest-securities.com

Matthieu Lavillunière, CFA
Technologie
+33 1 173 73 90 34
mlavilluniere@invest-securities.com

Thibaut Voglimacci
Medtechs / Biotechs
+33 1 44 88 77 95
tvoglimacci@invest-securities.com

Bruno Duclos
Immobiler
+33 1 173 73 90 25
bduclos@invest-securities.com

Benoît Faure-Jarrosson
Immobiler
+33 1 44 88 77 88
bfaure-jarrosson@invest-securities.com

Christian Guyot
Biens de Consommation
+33 1 80 97 22 01
cguyot@invest-securities.com

Matthieu Lavillunière
Technologie
+33 1 173 73 90 34
mlavilluniere@invest-securities.com

Johann Carrier
Stock-Picking
+33 1 44 88 77 88
jcarrier@invest-securities.com

Benoit Faure-Jarrosson
Immobiler
+33 1 44 88 77 88
bfaure-jarrosson@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Eric d’Aillières
Senior Advisor
+33 1 55 35 55 62
edaillières@invest-securities.com

François Habrias
Vente Institutionnelle
+33 1 155 35 55 70
fhabrias@invest-securities.com

Benoît Faure-Jarrosson
Immobiler
+33 1 44 88 77 88
bfaure-jarrosson@invest-securities.com

Christian Guyot
Biens de Consommation
+33 1 80 97 22 01
cguyot@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Ralph Olmos
Vente Institutionnelle
+33 1 55 35 55 72
rolmos@invest-securities.com

Kaspar Stuart
Vente Institutionnelle
+33 1 155 35 55 65
kstuart@invest-securities.com

Renaud Vallette Viallard
Vente Institutionnelle
+33 1 72 38 26 32
rvalletteviallard@invest-securities.com

Ralph Olmos
Vente Institutionnelle
+33 1 55 35 55 72
rolmos@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Amaury Dada
Chargé d’Affaires
+33 1 173 73 90 31
adada@invest-securities.com

Bertrand Le Mollé-Montanguon
Vente Institutionnelle
+33 1 155 35 55 74
blmmontanguon@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Claude Bouyer
Senior Advisor
+33 1 44 88 88 02
cbouyer@invest-securities.com

Frédéric Vals
Vente Institutionnelle
+33 1 55 35 55 71
fvals@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Johann Carrier
Stock-Picking
+33 1 44 88 77 88
jcarrier@invest-securities.com

Matthieu Lavillunière
Technologie
+33 1 173 73 90 34
mlavilluniere@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Amaury Dada
Chargé d’Affaires
+33 1 173 73 90 31
adada@invest-securities.com

Bertrand Le Mollé-Montanguon
Vente Institutionnelle
+33 1 155 35 55 74
blmmontanguon@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Amaury Dada
Chargé d’Affaires
+33 1 173 73 90 31
adada@invest-securities.com

Bertrand Le Mollé-Montanguon
Vente Institutionnelle
+33 1 155 35 55 74
blmmontanguon@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Johann Carrier
Stock-Picking
+33 1 44 88 77 88
jcarrier@invest-securities.com

Matthieu Lavillunière
Technologie
+33 1 173 73 90 34
mlavilluniere@invest-securities.com

Thierry Roussilhe
Responsable
+33 1 55 35 55 66
troussilhe@invest-securities.com

Amaury Dada
Chargé d’Affaires
+33 1 173 73 90 31
adada@invest-securities.com

Bertrand Le Mollé-Montanguon
Vente Institutionnelle
+33 1 155 35 55 74
blmmontanguon@invest-securities.com